Business Standard

Specialty scale-up, product mix: Sun's medicine cabinet piques brokerages

In the near term, higher R&D costs and a recent acquisition to weigh on earnings growth

Sun Pharma
Premium

Sun Pharma

Ram Prasad Sahu Mumbai
India’s largest listed pharmaceutical (pharma) company — Sun Pharmaceutical Industries (Sun Pharma) — is expected to maintain its outperformance vis-à-vis the sector’s, as its multiple bets on specialty products, improving product mix, recent acquisitions, and branded business are finding favour with brokerages.

While it has gained 7 per cent over the past year, the Nifty Pharma Index is down 13.6 per cent. Its outperformance over two years has been fairly evident, with the market leader gaining 66 per cent to Nifty Pharma’s minus 1.4 per cent.

Although analysts have reduced their near-term earnings estimates, given the ongoing investments, higher research

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Mar 27 2023 | 6:02 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com